Clinical trials: Moderate Dementia
Alzheimer Disease
Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
The study is to evaluate the safety, tolerability and whether there is an immune system response to multiple doses of ACC-001 with or without the use of a substance that may increase the response to the drug.
- Trial name
- NCT00752232
- Testing
- ACC-001, QS-21, PBS
- Where
- 10 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Pfizer
Alzheimer Disease
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
A two-year safety study of simufilam (PTI-125) 100 mg oral tablets twice daily for participants of the previous simufilam studies as wells as additional new mild-to-moderate Alzheimer's disease subjects for a total of 200…
- Trial name
- PTI-125 (NCT04388254)
- Testing
- Simufilam 100 mg oral tablet
- Where
- 17 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Cassava Sciences, Inc.
Alzheimer Disease
Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of mild to moderate Alzheimer disease. Subjects will be in the study for six months and will receive subcutaneous injections once per week.
- Trial name
- NCT00663026
- Testing
- bapineuzumab
- Where
- 17 sites in United States
- Volunteers
- 79 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine whether multiple dose administration is safe and well tolerated in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00945672
- Testing
- PF-04360365 10 mg/kg, PF-04360365 7.5 mg/kg
- Where
- 4 sites in Sweden
- Volunteers
- 36 people
- Sponsor
- Pfizer
Alzheimer Disease, Dementia of Alzheimer Type
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.
- Trial name
- LIFT-AD (NCT04488419)
- Testing
- ATH-1017
- Where
- United States
- Volunteers
- 554 people
- Sponsor
- LeonaBio
Alzheimer's Disease
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD.
- Trial name
- NCT03828747
- Testing
- Semorinemab, [18F]GTP1
- Where
- 49 sites in United States, France and 2 more
- Volunteers
- 272 people
- Sponsor
- Genentech, Inc.
Dementia of the Alzheimer's Type
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent…
- Trial name
- NCT00322153
- Testing
- memantine ER
- Where
- 83 sites in United States, Argentina and 2 more
- Volunteers
- 677 people
- Sponsor
- Forest Laboratories
Alzheimer Disease, Dementia, Alzheimer Type
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
This is a Phase 2 study to evaluate safety and efficacy in participants with Mild Cognitive Impairment due to Alzheimer's Disease/Prodromal Alzheimer's Disease (referred to as MCI/Prodromal) and mild to moderate dementia due to…
- Trial name
- NCT02322021
- Testing
- E2609
- Where
- 21 sites in United States
- Volunteers
- 70 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor
To establish efficacy of idalopirdine as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for symptomatic treatment of patients with mild-moderate Alzheimer's disease (AD).
- Trial name
- STARBRIGHT (NCT02006654)
- Testing
- Idalopirdine
- Where
- 107 sites in United States, Australia and 13 more
- Volunteers
- 734 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with…
- Trial name
- NCT02580305
- Testing
- SUVN-502, Donepezil, Memantine
- Where
- 71 sites in United States
- Volunteers
- 564 people
- Sponsor
- Suven Life Sciences Limited
Alzheimer's Disease
Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
The purpose of this study was to evaluate the efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild-moderate Alzheimer's disease.
- Trial name
- NCT00742417
- Testing
- Albutein 5%, Control
- Where
- 4 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Instituto Grifols, S.A.
Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute
Researching Resiliency in Stressful Experiences (RISE) Program for Men Leaving Incarceration
The investigators are conducting a randomized controlled trial to assess the impact of Resiliency in Stressful Experiences (RISE) - a comprehensive trauma-based program for young men releasing from a southeastern state's prisons.
- Conditions
- Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute, Depressive Symptoms, Anxiety
- Trial name
- NCT04785677
- Testing
- Resiliency in Stressful Experiences (RISE) Program
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Florida State University
Alzheimer Disease
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 weeks.
- Trial name
- RETHINK-ALZ (NCT04994483)
- Testing
- Simufilam
- Where
- 88 sites in United States, Australia and 1 more
- Volunteers
- 804 people
- Sponsor
- Cassava Sciences, Inc.
Alzheimer Disease
Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease
The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels. Subjects will receive either one of the 3 dosage levels of SAM-531, donepezil or placebo for the first 24 weeks of…
- Trial name
- NCT00895895
- Testing
- SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg
- Where
- 96 sites in United States, Argentina and 11 more
- Volunteers
- 526 people
- Sponsor
- Pfizer
Alzheimer Disease
Alzheimer's Disease Acitretin Medication
The trials investigates the changes of cerebral spinal fluid (CSF) soluble alpha-secretase cleaved APP (APPsα) levels under oral therapy with acitretin 30mg daily in patients with mild to moderate Alzheimer's disease (AD).The…
- Trial name
- ADAM (NCT01078168)
- Testing
- Acitretin
- Where
- 2 sites in Germany
- Volunteers
- 22 people
- Sponsor
- K. Lieb
Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001.
- Trial name
- "MAD" (NCT05363293)
- Testing
- AL001
- Where
- 2 sites in United States, Canada
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Alzamend Neuro, Inc.
Alzheimer's Disease
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil
To establish efficacy of idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).
- Trial name
- STARSHINE (NCT01955161)
- Testing
- Idalopirdine
- Where
- 137 sites in United States, Argentina and 14 more
- Volunteers
- 933 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
This study will evaluate the safety and Efficacy of donepezil in treatment of AD patients in China.
- Trial name
- STDMMAD (NCT02787746)
- Testing
- Donepezil
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Beijing Friendship Hospital
Alzheimer Disease
Effect of CT1812 Treatment on Brain Synaptic Density
Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.
- Trial name
- NCT03493282
- Testing
- Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Cognition Therapeutics
Alzheimer's Disease
Rasagiline Rescue in Alzheimer's Disease Clinical Trial
This is a Phase II, randomized, double blind, placebo controlled, parallel group, proof of concept three-site study, to evaluate the effect of Rasagiline in the regional brain metabolism on 18F-2-fluoro-2-deoxy-D-glucose…
- Trial name
- R2 (NCT02359552)
- Testing
- Rasagiline
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- The Cleveland Clinic